Becton, Dickinson and Co. launched a fully automated, high-throughput infectious disease molecular diagnostics platform in the United States on May 12.
The BD COR MX instrument is a new analytic option for the BD COR System diagnostic tool. The first test available on the new system is the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections — Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis — which can lead to several negative patient outcomes, including pregnancy complications and increased risk of HIV.
The BD COR MX/PX System integrates and automates molecular lab work, from sample processing to diagnostic test result. BD said its new system eliminates the need to sort specimens, enabling the lab tech to have very little interaction with the specimen and therefore giving him or her time for other lab processes.
The system allows 1,700 specimens to be loaded and is capable of delivering up to 1,000 sample results in 24 hours. Additionally, it can help reduce false positives by offering dual DNA targets for CT and GC detection together in the same sample and assay.
“Even before COVID-19, clinicians and laboratory technicians were faced with increasing workloads and patient needs, and now those challenges have been amplified significantly by the ongoing staffing shortages and further increased workloads caused by the pandemic,” said Brooke Story, president of integrated diagnostic solutions for BD. “By automating labor-intensive and mundane error-prone processes, the BD COR MX/PX System allows lab technicians and clinicians to focus on higher value work.”
Collection options for the BD CTGCTV2 assay include self-collection (in a clinical setting), vaginal/endocervical swab, urine (both male and female) and liquid-based cytology.